Archives
-
Nitrocefin in β-Lactamase Research
2026-10-05
An evidence-focused overview of Nitrocefin as a chromogenic cephalosporin substrate, its conceptual role in β-lactamase enzymatic activity measurement, and what published work on GOB-38 reveals about the limits of translating biochemical signals into antibiotic-resistance conclusions.
-
Thiamet G: O-GlcNAcase Inhibitor Evidence
2026-10-04
Thiamet G is a reported O-GlcNAcase inhibitor that increases cellular O-GlcNAc levels and has product-dossier evidence relevant to tau phosphorylation and leukemia-cell sensitization. A 2026 study links elevated O-GlcNAc modification with the HUWE1–TfR1 pathway in trophoblast ferroptosis, but it does not by itself establish Thiamet G efficacy in preeclampsia.
-
DPI and Plant Redox Defense: Five Questions
2026-10-03
A source-grounded overview of Diphenyleneiodonium chloride, its reported redox and cAMP-related activities, and what the 2025 citrus canker study does—and does not—show about ROS, iron uptake, and ferroptosis.
-
Deoxycholic Acid Sodium Salt in Assay Design
2026-10-02
Deoxycholic acid sodium salt is an ionic detergent whose value depends on controlled membrane disruption, protein recovery, and assay compatibility. This guide connects practical sample-preparation decisions with mechanistic lessons from the SNORA38B study in non-small cell lung cancer without implying that the reagent was used therapeutically.
-
Acetylcysteine as a Redox Probe in PDT Research
2026-10-01
Acetylcysteine can do more than replenish glutathione: it can help translational researchers test whether ROS are causal drivers of photodynamic therapy-induced pyroptosis. This article outlines how to use N-acetyl-L-cysteine as a carefully controlled mechanistic perturbation while avoiding overinterpretation across cancer, hepatic, respiratory, and neurodegenerative models.
-
BIRB 796: Rethinking p38α Translation
2026-10-01
BIRB 796 (Doramapimod) offers a highly selective allosteric route to p38α MAPK inhibition, but its translational value extends beyond potency alone. This article connects inflammatory signaling, apoptosis research, assay design, and emerging evidence that inhibitor-stabilized kinase conformations may influence phosphatase-driven pathway shutdown.
-
SP2509: Reliable LSD1 Assay Design
2026-09-30
This scenario-driven guide explains how SP2509 (SKU B4894) can improve experimental planning for AML viability, proliferation, apoptosis, and differentiation studies. It connects LSD1 biology with practical considerations including solvent compatibility, assay timing, endpoint interpretation, storage, and vendor selection.
-
EZ Cap EGFP mRNA 5-moUTP: Delivery Benchmark
2026-09-30
Explore how EZ Cap EGFP mRNA 5-moUTP can function as more than an EGFP reporter: it can help separate cargo performance from delivery-system behavior. This guide connects Cap 1 chemistry, 5-moUTP modification, and organ-targeted mRNA delivery to practical assay design.
-
GOB-38 in Elizabethkingia: Substrate Specificity
2026-09-29
The reference study characterizes GOB-38, a B3-Q metallo-β-lactamase from Elizabethkingia anophelis, and shows that it hydrolyzes penicillins, multiple cephalosporin generations, and carbapenems. Its recombinant-enzyme, genomic, and co-culture evidence connects active-site variation with broad β-lactam resistance and raises cautious concerns about resistance exchange during polymicrobial infection.
-
Pepstatin A for Reliable Cell Assays
2026-09-29
Learn how Pepstatin A (SKU A2571) can support better-controlled viability, proliferation, cytotoxicity, osteoclast, and viral protein-processing experiments. This scenario-based guide covers target selection, DMSO compatibility, treatment windows, orthogonal validation, and practical supplier evaluation.
-
Biomimetic Nanoplatform for Metastatic TNBC
2026-09-28
This ACS Nano study presents a biomimetic nanoplatform that combines 980 nm photothermal ablation with tumor-targeted delivery of the immune adjuvant R848 and an acid-responsive anti-PD-1 peptide. Its central contribution is the integration of primary tumor destruction, tumor-antigen release, and immune remodeling into one dendritic large-pore mesoporous silica nanoparticle system for metastatic triple-negative breast cancer.
-
Ruxolitinib in Sarcoma Immune-Profiling Workflows
2026-09-28
Ruxolitinib (INCB018424) offers a practical way to test how JAK1/2 blockade reshapes tumor and immune-cell responses, including in combination with oncolytic HSV. A murine sarcoma study shows why pairing treatment with high-dimensional spectral flow cytometry can reveal CD4 T-cell and germinal-center B-cell changes that narrower panels may miss.
-
From Reporter Signal to Lung-Targeted RNA Translation
2026-09-27
A practical framework for using Gaussia luciferase mRNA to interrogate LNP delivery, interpret reporter output, and connect formulation screening with the emerging design principles of lung-targeted RNA medicines.
-
Mutant p53-R280K Drives FASN-Dependent Breast Cancer
2026-09-26
A 2026 study reports that mutant p53-R280K partners with SREBP1 to activate FASN, increasing fatty acid synthesis and promoting breast cancer phenotypes in cell and mouse models. The findings define a p53-R280K/SREBP1/FASN pathway as a candidate metabolic vulnerability, while leaving its clinical relevance and transferability to other tumor contexts to be tested.
-
TAK-715: Interpreting p38 Inhibition Precisely
2026-09-25
TAK-715 is a potent p38 MAPK inhibitor for studying inflammatory signaling. This article explains how to distinguish reduced kinase output from changes in p38α phosphorylation—and why that distinction matters when interpreting cytokine and dephosphorylation assays.